Delivery Order SPE2DB20D1109-SPE2DB23FP15D
- Not listed
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order worth $15,397.08 for the supply of STELARA 90 MG/ML SYRINGEML. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of November 15, 2022. Amerisourcebergen is a major pharmaceutical distributor and healthcare solutions provider that plays a critical role in supplying medical products to federal government agencies,...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Stelara 90 mg/ml syringes. The $46,414.38 firm fixed-price delivery order is part of a larger Indefinite Delivery Contract (IDC) between the DLA Troop Support Medical and Cencora, Inc. (doing business as Amerisourcebergen), valued at up to $999,999,999.00 through November 2026. This single-award IDC serves as the primary vehicle for...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order worth $6,591.09 for the supply of STELARA 90 MG/ML syringes. The award was made by the Defense Logistics Agency (DLA), a component of the U.S. Department of Defense, and does not have a set-aside designation, indicating open competition. Amerisourcebergen, a major pharmaceutical distributor, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and subsidiary of Cencora, Inc. The $6,715.70 firm-fixed-price delivery order is for the supply of Stelara 90 mg/mL syringes. This award falls under Amerisourcebergen's $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to support military...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of Stelara 90 mg/ml syringes. The $19,167.87 firm-fixed-price delivery order was issued by the Defense Logistics Agency (DLA) and has an ultimate completion date of October 19, 2023. The contract is not designated as a set-aside. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, as well as a separate...
- This federal contract award is for the delivery of Stelara 90 mg/ml syringes from Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to the Defense Logistics Agency (DLA). The $14,837.35 firm fixed-price delivery order was issued under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Cencora, Inc. (doing business as Amerisourcebergen) holds with the DLA Troop Support Medical. This IDC, which runs through November 2026, serves as the primary vehicle...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., was issued by the Defense Logistics Agency (DLA) Medical Supply Chain for the delivery of Stelara 90 mg/ml syringes. The Firm Fixed Price delivery order, valued at $12,715.97, has an ultimate completion date of March 13, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Stelara 90 mg/mL syringes. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen's parent company, Cencora, Inc., holds with the DLA Troop Support Medical. This IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the delivery of STELARA 90 MG/ML SYRINGEML. The $14,309.70 firm fixed price delivery order has a completion date of November 20, 2024. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Stelara 45 mg/0.5 ml syringes. The contract, valued at $3,281.21, is a firm fixed-price delivery order with a completion date of March 22, 2022. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 with the DLA...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB23FP15DDelivery Order
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of Stelara 90 mg/ml syringes. The $11,265.74 Firm Fixed Price Delivery Order was issued by the Defense Logistics Agency (DLA) with a performance period through May 18, 2023. The contract does not have a set-aside designation, indicating it was competitively awarded. Amerisourcebergen is a major pharmaceutical distributor that provides a wide range of medical products and supplies to support the Department of Defense and Department of Veterans Affairs healthcare systems. The company holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a primary vehicle for delivering essential pharmaceutical commodities to military treatment facilities worldwide. Additionally, Amerisourcebergen maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.3k | 5/17/23 |